Company: STAA
Filing Date: 2025-10-30
Form Type: DEFA14A
Source: 0001193125-25-258558
Chunk: 21

Company: STAAR SURGICAL CO
Filing Date: 2025-10-30
Form: DEFA14A
Chunk 21
---
 release in regards to the same.

On August 8, 2025, Alcon filed a current report on Form 6-K announcing the transaction.

Also on August 8, 2025, Broadwood
filed a Schedule 13D/A with the SEC disclosing beneficial ownership of 27.3% of the outstanding STAAR common stock. Broadwood’s filing indicated it had not decided whether to vote in favor of the Merger, against the Merger, or in favor of a
superior offer. Further, the Schedule 13D/A noted that Broadwood would be seeking additional documents and information relating to the process that led to the signing of the Merger Agreement to inform its voting decision and was planning to explore
strategic alternatives to the Merger.

On September 2, 2025, Broadwood filed a Schedule 13D/A and issued a related press release
indicating, among other things, that Broadwood intends to vote against the Merger Proposal. On September 15, 2025, Broadwood and other members of the Broadwood Group filed a preliminary proxy statement with the SEC to solicit votes of STAAR
stockholders in opposition to the Board’s recommendations on the Merger Proposal and Compensation Proposal presented in this proxy statement.

On September 22, 2025, affiliates of Yunqi Capital Limited, a beneficial owner of approximately 5.1% of the outstanding shares of STAAR common stock, announced in a press release their opposition to the Merger, and it reiterated its position in a letter to STAAR stockholders dated October 7, 2025.

Also on September 22, 2025, STAAR announced in a press release that it had received no competing proposals during the 45-day “window shop” period, which ended on September 19, 2025, despite Broadwood’s active exploration of alternative buyers of STAAR during the 45-day “window shop” period.

On September 24, 2025, the Broadwood Group filed a definitive proxy statement with the SEC to solicit votes of STAAR stockholders in opposition to the Board’s recommendations on the Merger Proposal and the Compensation Proposal presented in this proxy statement.

On September 26, 2025, STAAR published an investor presentation highlighting the stockholder value presented by the Merger, and announced that Soleus Capital Master Fund, L.P. (“Soleus”), beneficial owner of approximately 6% of the outstanding shares of STAAR common stock and STAAR’s